Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study
-
- Mark H Einstein
- Montefiore Medical Center; Albert Einstein College of Medicine; Department of Obstetrics & Gynecology and Women's Health; Bronx, NY USA
-
- Myron J Levin
- University of Colorado Denver and Health Sciences Center; Aurora, CO USA
-
- Archana Chatterjee
- University of South Dakota; Sanford School of Medicine and Sanford Children's Specialty Clinics; Sioux Falls, SD USA
-
- Nahida Chakhtoura
- University of Miami; Miami, FL USA
-
- Peter Takacs
- University of Miami; Miami, FL USA
-
- Grégory Catteau
- GlaxoSmithKline Vaccines; Belgium
-
- Francis J Dessy
- GlaxoSmithKline Vaccines; Belgium
-
- Philippe Moris
- GlaxoSmithKline Vaccines; Belgium
-
- Lan Lin
- XPE Pharma & Science, Wavre, Belgium, on behalf of GlaxoSmithKline Vaccines
-
- Frank Struyf
- GlaxoSmithKline Vaccines; Belgium
-
- Gary Dubin
- GlaxoSmithKline Vaccines; King of Prussia, PA USA
収録刊行物
-
- Human Vaccines & Immunotherapeutics
-
Human Vaccines & Immunotherapeutics 10 (12), 3455-3465, 2014-11
Informa UK Limited
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1360855568995656320
-
- DOI
- 10.4161/hv.36117
-
- ISSN
- 2164554X
- 21645515
-
- データソース種別
-
- Crossref